Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Completed · Phase 3

Conditions studied: Deep Vein Thrombosis

In brief

Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.

Key facts

Study ID

NCT00067093

Run by

Sanofi

People needed

1452

Starts

2003-05-01

Expected to finish

2005-09-01

Last updated by the study team

2011-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed acute symptomatic DVT
• Written informed consent

You may not qualify if…

• Legal lower age limitations
• Patients with symptomatic pulmonary embolism
• Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT
• Other indication for VKA than DVT
• More than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of VKA treatment prior to randomization
• Participation in another pharmacotherapeutic study within the prior 30 days
• Creatinine clearance <10mL/min, severe hepatic disease or bacterial endocarditis
• Life expectancy <3 Months
• Active bleeding or high risk for bleeding
• Uncontrolled hypertension: systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg.
• Pregnancy or childbearing potential without proper contraceptive measures
• Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin (UFH), enoxaparin, or tinzaparin

Where it is running

• University of Colorado Health Sciences Center — Denver, Colorado, United States
• Jackson Cardio-Vascular Clinic — Jacksonville, Florida, United States
• MIMA Century Research Associates — Melbourne, Florida, United States
• Medical College of Georgia — Augusta, Georgia, United States
• DeKalb Medical Center — Decatur, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• Evanston Northwestern Healthcare — Evanston, Illinois, United States
• Loyola University of Chicago — Maywood, Illinois, United States
• Consultants in Pulmonary Medicine — Olathe, Kansas, United States
• Boston Medical Center — Boston, Massachusetts, United States
• St. Joseph Mercy - Oakland Research Center — Pontiac, Michigan, United States
• Lovelace Health Systems — Albuquerque, New Mexico, United States
• North Shore University Hospital — Manhasset, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Health System Research Center — Grand Forks, North Dakota, United States
• University of Oklahoma HSC — Oklahoma City, Oklahoma, United States
• Lehigh Valley Hospital — Allentown, Pennsylvania, United States
• James Muntz — Houston, Texas, United States
• Scott and White Memorial Hospital & Clinic — Temple, Texas, United States
• Inova Alexandria Hospital — Alexandria, Virginia, United States
• Pulmonary Associates — Fredericksburg, Virginia, United States
• McGuire VAMC — Richmond, Virginia, United States
• Swedish Medical Center — Seattle, Washington, United States
• William Dittman — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.